AUTH/3759/4/23 - Complainant v Boehringer Ingelheim

Activity at the British Sarcoma Group Conference 2023

  • Case number
    AUTH/3759/4/23
  • Complaint received
    04 April 2023
  • Completed
    28 May 2024
  • Appeal hearing
    No appeal
  • Applicable Code year
    2021
  • No breach Clause(s)
  • Additional sanctions

Case Summary

This case related to the allegations about the distribution of flyers concerning a Phase 2/3 clinical trial to delegates at the BSG Conference.

The outcome under the 2021 Code was:

No Breach of Clause 3.1

Requirement that a medicine must not be promoted prior to the grant of its marketing authorisation

No Breach of Clause 5.1

Requirement to maintain high standards at all times

No Breach of Clause 5.6

Requirement that material should only be made available to those groups of people whose need for or interest in it can reasonably be assumed

No Breach of Clause 6.1

Requirement that information must be accurate, up-to-date and not misleading


This summary is not intended to be read in isolation.
For full details, please see the full case report below.